Search
Pegunigalsidase alfa
go.drugbank.com/drugs/DB14992ApprovedInvestigationalPegunigalsidase alfa (PRX-102) is a recombinant form of human α-galactosidase-A indicated for long-term enzyme replacement therapy in patients with Fabry disease, a rare genetic disorder characterized … [L46342,L46387] Later on, the FDA approved pegunigalsidase alfa for the treatment of adult patients with Fabry disease that same month.[L46432,L46437]
Mycophenolic acid
go.drugbank.com/drugs/DB01024ApprovedInvestigationalMycophenolic acid is used in immunosuppressive regimens as part of a triple therapy that includes a calcineurin inhibitor (ciclosporin or tacrolimus) and prednisolone.
Rimegepant
go.drugbank.com/drugs/DB12457ApprovedInvestigationalsafer for use in patients with contraindications to standard therapy. … [L11028] It received FDA approval on February 27, 2020 for the acute treatment migraine headache,[L11974] and was subsequently approved by the European Commission in April 2022 for both the treatment and
Hexetidine
go.drugbank.com/drugs/DB08958ApprovedWithdrawnIt is used as a 0.1% mouthwash for local infections and oral hygiene.
Categories: Antiinfectives and Antiseptics for Local Oral TreatmentNemolizumab
go.drugbank.com/drugs/DB15252ApprovedInvestigational[A264274] It was later approved by the FDA on August 13, 2024, for the treatment of prurigo nodularis.[L51169] … [L51159] Nemolizumab gained its first global approval in Japan on March 28, 2022, for the treatment of atopic dermatitis.
Categories: Agents for Dermatitis, Excluding CorticosteroidsFactor XIII (human)
go.drugbank.com/drugs/DB12909ApprovedInvestigationalFor people with congenital deficiency or mutation of Factor XIII, a rare bleeding disorder, exogenous replacement of this key coagulation factor is essential for management and prevention of bleeding episodes … Factor XIII (human) is a heat-treated, lyophilized concentrate of coagulation factor XIII, an endogenous enzyme responsible for the crosslinking of fibrin and an essential component of the coagulation
Enasidenib
go.drugbank.com/drugs/DB13874ApprovedInvestigationalPatients eligible for this treatment are selected by testing the presence of IDH2 mutations in the blood or bone marrow. … Enasidenib is an orally available treatment for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with specific mutations in the isocitrate dehydrogenase 2 (IDH2)
Pemigatinib
go.drugbank.com/drugs/DB15102ApprovedInvestigationalThis malignancy accounts for 15% to 20% of primary hepatobiliary malignancies, which account for 13% of overall cancer-related global mortality. … [A193716] In April 2020, pemigatinib was approved by the FDA for the treatment of unresectable locally advanced or metastatic cholangiocarcinoma in previously treated adult patients with a fibroblast
Difluprednate
go.drugbank.com/drugs/DB06781ApprovedInvestigationalDifluprednate is abbreviated DFBA, or difluoroprednisolone butyrate acetate. It is indicated for treatment of endogenous anterior uveiti. … Difluprednate is a topical corticosteroid indicated for the treatment of infammation and pain associated with ocular surgery. It is a butyrate ester of 6(α), 9(α)-difluoro prednisolone acetate.
Revakinagene taroretcel
go.drugbank.com/drugs/DB05344ApprovedInvestigational[A265115] On March 6, 2025, FDA approved revakinagene taroretcel for the treatment of idiopathic macular telangiectasia type 2. … encapsulated cell-based gene therapy that contains 200,000 to 440,000 allogeneic retinal pigment epithelial cells expressing recombinant human ciliary neurotropic factor (rhCNTF) (NTC-201-6A cell line) for